Sittner & Nelson’s Vertex Pharmaceuticals VRTX Stock Holding History

Sittner & Nelson’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$275K	Hold	615	–	–	0.1%	139
2025 Q4	$294K	Hold	615	–	–	0.1%	126
2025 Q3	$241K	Hold	615	–	–	0.09%	133
2025 Q2	$274K	Buy	615 +17	+3%	+$7.83K	0.11%	120
2025 Q1	$290K	Hold	598	–	–	0.12%	114
2024 Q4	$241K	Hold	598	–	–	0.1%	113
2024 Q3	$278K	Hold	598	–	–	0.12%	110
2024 Q2	$280K	Hold	598	–	–	0.14%	91
2024 Q1	$250K	Hold	598	–	–	0.13%	104
2023 Q4	$243K	Buy	598 +300	+101%	+$111K	0.13%	100
2023 Q3	$104K	Buy	298 +60	+25%	+$21K	0.06%	148
2023 Q2	$83.8K	Hold	238	–	–	0.05%	160
2023 Q1	$75K	Buy	238 +113	+90%	+$33.9K	0.04%	181
2022 Q4	$36.1K	Hold	125	–	–	0.02%	242
2022 Q3	$36K	Sell	125 -59	-32%	-$17K	0.02%	236
2022 Q2	$52K	Buy	184 +59	+47%	+$15.8K	0.03%	211
2022 Q1	$33K	Buy	125 +50	+67%	+$11.9K	0.02%	234
2021 Q4	$16K	Sell	75 -25	-25%	-$4.86K	0.01%	295
2021 Q3	$18K	Hold	100	–	–	0.01%	267
2021 Q2	$20K	Buy	+100	New	+$20.9K	0.01%	245

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sittner & Nelson's VRTX Position: Q1 2026 in Review

Sittner & Nelson held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 615 shares worth $275K. The position accounts for 0.1% of the portfolio, ranked #139.

Sittner & Nelson first reported a position in VRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $294K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Sittner & Nelson held 615 shares of Vertex Pharmaceuticals worth $275K as of Q1 2026.
Sittner & Nelson left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.1% of Sittner & Nelson's portfolio in Q1 2026, its #139 holding.
Sittner & Nelson first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
Sittner & Nelson's Vertex Pharmaceuticals position peaked at $294K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Sittner & Nelson's 13F filing for Q1 2026, filed 12 May 2026.